Compare CARS & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CARS | TRDA |
|---|---|---|
| Founded | 1998 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Motor Vehicles | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 476.1M | 481.6M |
| IPO Year | 2017 | 2021 |
| Metric | CARS | TRDA |
|---|---|---|
| Price | $10.23 | $14.02 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | $16.00 | ★ $21.00 |
| AVG Volume (30 Days) | ★ 1.4M | 158.9K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.32 | N/A |
| Revenue | ★ $723,239,000.00 | $25,421,000.00 |
| Revenue This Year | $2.97 | $39.97 |
| Revenue Next Year | $2.48 | $50.80 |
| P/E Ratio | $31.58 | ★ N/A |
| Revenue Growth | ★ 0.57 | N/A |
| 52 Week Low | $7.40 | $4.93 |
| 52 Week High | $13.97 | $14.49 |
| Indicator | CARS | TRDA |
|---|---|---|
| Relative Strength Index (RSI) | 70.32 | 58.28 |
| Support Level | $10.21 | $10.84 |
| Resistance Level | $13.66 | $13.99 |
| Average True Range (ATR) | 0.38 | 0.73 |
| MACD | 0.29 | 0.08 |
| Stochastic Oscillator | 98.54 | 76.92 |
Cars.com Inc is an audience-powered and data-driven technology platform that simplifies buying and selling cars. The flagship Cars.com marketplace connects consumers to dealerships across the U.S., powering the car-buying experience with artificial intelligence (AI) shopping tools, vehicle reviews and content. Its ecosystem of products enables dealers and OEMs to sell more cars by leveraging the marketplace, dealer websites, trade and appraisal tools and proprietary in-market media solutions. The platform provides shoppers with data, resources and digital tools to make informed buying decisions and connect with automotive retailers. The Company also provides dealerships and OEMs with solutions and data-driven intelligence to reach and influence its 26 million monthly shoppers.
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.